Tyrosine hydroxylase deficiency

Roser Pons MD

Neurogenetic Disorders

Updated 11.17.2022
Released 07.08.2015
Expires For CME 11.17.2025

Tyrosine hydroxylase deficiency

Author: Roser Pons MD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

Tyrosine hydroxylase deficiency

In This Article

Quick Link

Introduction

Overview

Tyrosine hydroxylase deficiency is an autosomal recessively inherited inborn error of metabolism that involves the biosynthesis of catecholamines (dopamine, epinephrine, and norepinephrine). The clinical presentation ranges from severe infantile parkinsonism to a phenotype reminiscent of dopa-responsive dystonia. Diagnosis is based on the pattern of monoamine metabolites in CSF and the molecular analysis of the TH gene.

Key points

	• Tyrosine hydroxylase deficiency is an autosomal recessively inherited disorder that leads to a deficient production of catecholamines (dopamine, epinephrine, and norepinephrine).
	• Patients usually exhibit developmental delay, infantile parkinsonism, dystonia, oculogyric crises, and features of autonomic dysfunction. Milder phenotypes may also occur.
	• Tyrosine hydroxylase deficiency is diagnosed by detection of decreased CSF concentrations of the downstream metabolites of catecholamine degradation, homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol.
	• The treatment of choice is levodopa; alternatively, patients are treated with other dopaminergic drugs, mainly dopamine agonists and monoamine oxidase inhibitors.

Historical note and terminology

Tyrosine hydroxylase deficiency was first reported in 1971 in 2 brothers with early-onset progressive dopa-responsive dystonia (03). Subsequently, young infants with a more severe phenotype were recognized (12). In 2010, Willemsen and colleagues described the largest series reported to date (36 patients) and proposed 2 phenotypes: type A, which has an onset in infancy or childhood, is less severe, has a better prognosis, and is L-dopa responsive; and type B, which has an earlier onset (neonatal period, early infancy), is more severe, and is poorly L-dopa responsive (32). This classification was widely used by clinicians and researchers, although the authors acknowledge that the phenotype of tyrosine hydroxylase deficiency has a spectrum with overlap of clinical features between both groups (32). A standardized deep phenotyping study from the registry of the International Working Group on Neurotransmitter Related Disorders did not find clear differences in perinatal abnormalities, postnatal problems, and achievement of gross motor milestones; drug response varied regardless of the age of initial symptoms (16). Consequently, the authors proposed to abandon this classification. Currently, more than 70 cases have been reported worldwide (32; 07).

In 1996 the first mutations in the tyrosine hydroxylase gene were reported (21). The spectrum of mutations is heterogenous with no hot spots detected (15; 07). Two common mutations due to founder effects have been detected, one in the Greek population (c.707C> T) (25) and another in the Dutch population (c.698G> A) (31).

Clinical manifestations

Presentation and course

The age of presentation of tyrosine hydroxylase deficiency ranges from the neonatal period to childhood, and the clinical phenotype ranges from a severe phenotype of encephalopathy and infantile parkinsonism-dystonia to a moderate phenotype reminiscent of dopa-responsive dystonia (Segawa disease). This phenotypic continuum of severity also applies to other monoamine neurotransmitter disorders (15).

The majority of patients became symptomatic during infancy (between 1 and 15 months) and manifest with severe developmental delay and hypotonia. On examination, patients show features of infantile parkinsonism characterized by hypokinesia, bradykinesia, and dystonia of variable severity. They often suffer oculogyric crises, which are episodes of dystonia characterized by intermittent or sustained upgaze deviation with variable association of axial and/or limb dystonic posturing lasting minutes to hours. Less severely affected patients present later in childhood with gait difficulties associated with dystonia or parkinsonian features (09; 16).

Patients with a more severe phenotype exhibit symptoms during the neonatal period or in early infancy and are profoundly hypokinetic; they have minimal or no motor developmental acquisitions and suffer dystonic crises with regular intervals every 4 to 5 days. They are often irritable and can suffer “lethargy-irritability crises” that are characterized by features of autonomic dysfunction (excessive drooling, sweating, body temperature instability) especially during periods of dystonia (32; 15; 26).

Atypical features and presentations have also been described and include early-onset spastic paraplegia, dopa-responsive myoclonus-dystonia, and acute episodes of motor deterioration (08; 23; 28; 11; 13).

Signs of autonomic dysfunction, including excessive sweating, temperature instability and nasal congestion, often occur in infants with tyrosine hydroxylase deficiency. Sleep disturbances during infancy are also reported often in the form of excessive sleep (32; 15; 26). Hormonal manifestations that may occur in tyrosine hydroxylase deficiency include growth retardation and delayed bone age (12). Furthermore, a high frequency of these patients are small-for-gestation age and have birth lengths below the 10th percentile (16b). In addition, hyperprolactinemia is also a characteristic feature because dopamine inhibits prolactin secretion. Galactorrhea has been reported in several patients with tyrosine hydroxylase deficiency (33).

Prognosis and complications

The response to L-dopa therapy in tyrosine hydroxylase deficiency depends on the severity of the phenotype, which in turn is reflected by the concentrations of homovanillic acid and the HVA/5-HIA ratio in CSF (32). Response to treatment varies from minimal or no response in severe phenotypes to slow and gradual responses with escalation of L-dopa dose in moderate phenotypes and dramatic favorable response within days in phenotypes reminiscent of Segawa disease. Responders show improvement in hypokinesia, tremor, and dystonia, and oculogyric crises decrease in frequency and severity and may eventually disappear (32; 34; 26). It is generally accepted that early diagnosis and prompt treatment improves the final motor and cognitive outcome in tyrosine hydroxylase-deficient patients (32; 15).

Some patients with phenotypes of mild and moderate severity and favorable response to L-dopa therapy reach full normalization of neurologic condition, whereas others continue having some mild motor impairments. Patients can experience dyskinesias induced by L-dopa, which tend to improve with time, and, in certain cases, they may subside with no need for further management (32; 34; 26). Response to L-dopa generally remains stable over the years. However, a report on long-term outcome of patients with phenotypes reminiscent of dopa-responsive dystonia showed that 15% of patients manifest motor symptoms and paroxysmal events related to dopamine insufficiency (20).

Patients with severe phenotypes show a worse but variable outcome. A number of them show minimal or no response in motor function, whereas others show a slow and gradual response and are able to gain motor milestones over the course of months to years. They usually show variable degrees of motor impairment, and their condition remains stable over the years with no evidence of progressive disease. Although these patients generally show more problems with L-dopa-induced dyskinesias, their tolerance improves over time (32; 34; 26; 18).

Cognitive development is impaired in many individuals with tyrosine hydroxylase deficiency (32; 18). Although systematic assessment of cognitive profiles is lacking, Willemsen and colleagues reported mild to moderate intellectual disability in 91% of patients with severe phenotypes, and in 33% with mild to intermediate phenotypes. Long-term follow up did not reveal any signs of further cognitive decline in any of the tested patients (32).

Clinical vignette

The patient, a female, was the product of an uncomplicated pregnancy and an unremarkable perinatal period. At 2.5 months of age, she exhibited hand and leg tremors when crying. At 3 to 4 months of life, she started having episodes of eye rolling upwards associated with limb posturing (oculogyric crises). These episodes lasted 2 to 6 hours and occurred mainly in the late afternoon every 4 days. EEG recording during these paroxysmal episodes did not show any epileptiform activity, but she was treated with antiepileptic drugs with no favorable response. Her brain MRI was normal.

At the age of 2 years, she had not achieved any motor development. She had no head or trunk control. She was able to hold an object in her hand, but she could not reach. Although her motor performance was minimal, her parents noted that she was more active in the mornings and after a nap. She understood simple commands and babbled occasionally. On review of systems, she had increased sweating, a chronically stuffed nose, and constipation.

On exam, her vital signs were stable. Her head circumference was 50 cm. She had a narrow and long face, tented mouth, small hands, and mild gingival hypertrophy and was perspiring profusely. She was alert and appeared oriented and aware of her surroundings. She had bilateral ptosis with full extraocular movements and poor facial expression. Her cry was strong. She had no head control, and her spontaneous movements were minimal. Mild twitching of fingers and face was noted consistent with chorea. Although she appeared hypotonic when in her mother’s arms, she developed dystonic posturing and stiffness of limbs and neck when manipulated. Her deep tendon reflexes were hyperactive, and she had spontaneous up-going toes. No tremor was noted. The parents stated that the tremor previously noted had disappeared gradually during the first year of life.

Neurotransmitter metabolites were measured in CSF. A marked reduction of homovanillic acid concentrations with normal serotonin metabolites as detected. Sequencing analysis of the tyrosine hydroxylase gene revealed a homozygous mutation in exon 6 (c.707T> C).

She was started on L-dopa-carbidopa at 1 mg/kg-1 d-1, and the dose was increased gradually every month. Despite the gradual increase in the L-dopa dose, she developed jaw opening dystonia and generalized dyskinesias. Amantadine (4 mg/kg-1 d-1) was added at 3.5 years of age, and this was followed by a reduction of dyskinesias, which allowed further increases in the L-dopa dose.

Her motor development gradually improved. She walked independently at the age of 5 years, and she speaks with dysarthria and attends special education classes at the age of 10 years. She is fidgety, her gait is mildly dyskinetic, and she is independent in all her daily activities.

Biological basis

Etiology and pathogenesis

Tyrosine hydroxylase deficiency is caused by mutations in the tyrosine hydroxylase gene on chromosome 11p15.5. Tyrosine hydroxylase is a specific tetrabiopterin-dependent amino acid hydroxylase that converts tyrosine to dihydroxyphenylalanine (L-dopa), the rate-limiting step in the synthesis of catecholamines, dopamine, epinephrine, and norepinephrine (15). In the brain, tyrosine hydroxylase is mainly expressed in dopaminergic neurons in the ventral tegmental area and substantia nigra pars compacta and in the noradrenergic neurons of the locus coeruleus. In the periphery, tyrosine hydroxylase is mainly found in sympathetic neurons and in the adrenal medulla (07).

Monoamine neurotransmitters include serotonin and catecholamines. They play important roles in modulation of psychomotor function and hormone secretion as well as cardiovascular, respiratory, and gastrointestinal control, sleep mechanisms, body temperature, and pain.

The starting substrate for the formation of catecholamines is tyrosine and for serotonin is tryptophan. Tyrosine is converted to L-dopa by tyrosine hydroxylase and tryptophan to 5-hydroxytryptophan by tryptophan hydroxylase. L-dopa and 5-hydroxytryptophan undergo decarboxylation through the action of aromatic amino acid decarboxylase, leading to the formation of dopamine and serotonin, respectively. Within noradrenergic neurons, dopamine is converted to norepinephrine, and within the adrenal medulla, norepinephrine is methylated to form epinephrine. Dopamine and serotonin are released and rapidly catabolized. Through the action of monoamine oxidase and catechol-O-methyltransferase, 5-hydroxyindolacetic acid (5-HIAA) is produced from serotonin, homovanillic acid from dopamine, and 3-methoxy-4-hydroxyphenylglycol from norepinephrine.

Metabolic pathway of biogenic amines

Disorders of monoamine biosynthesis lead to reduced synthesis of specific neurotransmitters, and their clinical manifestations are caused by the deficiency of these neurotransmitters in the brain and peripheral nervous system. Tyrosine hydroxylase deficiency leads to reduced synthesis of all catecholamines. Reduced concentrations of dopamine are thought to be the cause of the motor symptoms, given dopamine’s role in coordination and regulation of movement. This has been shown in homozygous tyrosine hydroxylase knock-in mice that exhibited a gradual loss of central catecholamines and severe motor impairment, including rigidity, dystonia, impaired motor coordination, and bradykinesia (14). Norepinephrine and epinephrine deficiency are responsible for the manifestations of autonomic sympathetic dysfunction. Given the role of monoamines on hormonal function, endocrine dysfunction may also occur. Some clinical manifestations, such as cognitive disturbances, cannot be attributed to the deficit of a specific neurotransmitter. The early effects of dopamine deficiency in the developing brain may account for these disturbances. This is supported by animal models that have shown structural abnormalities in brain development, particularly in the growth and laminar organization of the cerebral cortex (19). Further support comes from the study of a tyrosine hydroxylase-deficient human fetus that demonstrated a decrease in the expression of developmental markers for synapses, axons, and dendrites (30).

Further pathophysiological mechanisms in tyrosine hydroxylase deficiency include changes in receptor sensitivity implicated in the drug-induced dyskinesias that are often observed in these patients (26).

Differential diagnosis

Associated or underlying disorders

Differential diagnosis of tyrosine hydroxylase deficiency includes other disorders of monoamine synthesis, such as aromatic amino acid decarboxylase deficiency and pterin disorders. These disorders lead to severe dopamine deficiency from early infancy, which manifest with infantile parkinsonism, oculogyric crises, and autonomic dysfunction. In moderate phenotypes of tyrosine hydroxylase deficiency that present in childhood with gait disorders and dystonia, differential diagnosis also includes Segawa disease. Associated clinical manifestations and biochemical findings, including blood phenylalanine concentration and CSF pattern of monoamine catabolites and pterins, allow the differentiation of these defects. Measurement of enzyme activity in some cases and molecular studies can confirm the diagnosis (15).

Epileptic encephalopathy is also considered in the differential diagnosis of severe cases of tyrosine hydroxylase deficiency because oculogyric crises are associated with prominent dystonic posturing that may be misdiagnosed as seizures. Unresponsiveness to antiepileptic drugs and the presence of infantile parkinsonism and autonomic dysfunction together, with the lack of EEG correlate during episodes, should suggest a defect in monoamine synthesis (15).

Because severe forms of tyrosine hydroxylase deficiency can be associated with perinatal complications, a differential diagnosis with neonatal infectious, hypoxic ischemic, epileptic, and metabolic disorders must be considered. Given the profound hypotonia and hypokinesia associated with ptosis and hypomimia that these patients show, neuromuscular disorders are also considered in the differential diagnosis. Finally, moderate forms of tyrosine hydroxylase deficiency can also mimic cerebral palsy and hereditary or acquired forms of juvenile parkinsonism. Medical history, clinical manifestations, and biochemical and genetic investigations can confirm the diagnosis (15).

Diagnostic workup

Concentrations of the monoamine neurotransmitter catabolites reflect the turnover of these neurotransmitters in the brain. Therefore, the diagnosis of tyrosine hydroxylase deficiency relies on the measurement of the monoamine catabolites homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, and 5-HIAA in CSF. The typical biochemical CSF pattern is a decreased homovanillic acid and 3-methoxy-4-hydroxyphenylglycol concentrations and low HVA/5-HIAA ratios with normal concentrations of pterins metabolites (26). It is important to note that collection and handling of CSF must be performed under appropriate conditions given the rostro-caudal gradient of these metabolites and the tendency for oxidation of some of them (15).

Measurements of dopamine precursor amino acids or catecholamines in blood or urine are in general noninformative. However, if differential diagnosis with other disorders of monoamine synthesis are considered, measurement of phenylalanine concentrations and analysis of tyrosine and phenylalanine concentrations after a load of phenylalanine may be necessary (phenylalanine loading test). Plasma prolactin measurement is an indicator of dopamine status because dopamine downregulates prolactin synthesis by the hypothalamus; thus, hyperprolactinemia is expected when dopamine deficiency occurs (15).

Neuroimaging is nondiagnostic. Brain MRI is normal in most patients with tyrosine hydroxylase deficiency, but approximately one third of patients show brain atrophy and, rarely, delayed myelination (16). Some children with severe phenotypes may also show nonspecific white-matter abnormalities and increased extracerebral CSF spaces (15).

Molecular analysis of the tyrosine hydroxylase gene confirms the diagnosis. To date, 40 different disease-related missense mutations, 5 nonsense mutations, 3 mutations in the promoter region, and 2 deletions have been reported (07; 23; 01). Most mutations are private, except for the 707T>C mutation in patients of Greek origin, and the 698G>A mutation in Dutch patients (31; 25). Functional studies of some missense variants revealed specific kinetic anomalies and altered substrate binding (p.Arg233His, p.Gly247Ser, p.Phe375Leu, and p.Cys359Phe) (07). Genotype-phenotype correlations have been difficult to demonstrate because patients are often compound heterozygotes except for patients with mutations in the promoter region of the TH gene, which is associated with milder phenotypes (23; 28).

Management

The mainstay of treatment in tyrosine hydroxylase deficiency is restoring dopaminergic neurotransmission by administering L-dopa, the primary metabolite that is deficient in this condition. Response and tolerance to L-dopa therapy is variable and depends on the severity of the phenotype. For this reason, therapy in tyrosine hydroxylase-deficient patients needs to be tailored on an individual basis. The starting dose of L-dopa, its escalation, and dosing frequency and the need for the addition of other agents to potentiate dopamine transmission are different in each patient (26).

The second most often used pharmacological strategy to potentiate dopaminergic neurotransmission involves inhibition of dopamine catabolism via the selective type B monoamine oxidase inhibitor, selegiline. Other inhibitors of dopamine degradation, such as catechol-O-methyl transferase inhibitors, and dopamine receptor agonists, ropinirole, pramipexole, bromocriptine, have only been tried sporadically in tyrosine hydroxylase-deficient patients (06; 32; 28).

Some of the first patients with tyrosine hydroxylase deficiency underwent serial lumbar punctures in order to monitor treatment efficacy biochemically. Irrespective of the clinical response, homovanillic acid concentrations increased with treatment but rarely reached normal concentrations (32; 34). Currently, serial monitoring of metabolites in CSF is performed in selected cases. Determination of prolactin concentrations has been proposed as a functional parameter to tailor therapy in dopamine deficiency disorders. However, there are marked fluctuations of prolactin during the day that cannot be attributed to variations in L-dopa dosing. Thus, determination of prolactin is used as an indicator of insufficient dopamine production (12).

L-dopa. L-dopa is coadministered with a peripheral decarboxylase inhibitor carbidopa or benserazide in order to prevent conversion of L-dopa to dopamine peripherally, thus, increasing L-dopa brain bioavailability and decreasing its peripheral dose-related side effects. Tolerance to L-dopa treatment usually refers to the appearance of dyskinesias that may manifest with small doses of L-dopa even at the initiation of treatment, especially in children with the severe infantile disorder (32; 26). On the other hand, common dose-dependent adverse effects of L-dopa, such as nausea, vomiting, and hypotension, are rarely seen in these patients. Disabling L-dopa-related panic attacks were reported in one case (27).

In general, older children with phenotypes resembling Segawa disease are treated with L-dopa at 150 to 250 mg/d (08; 27), whereas younger patients with infantile parkinsonism are treated with starting doses of L-dopa at 0.1 to 1 mg/k/d divided in 3 to 6 doses a day. L-dopa is then increased gradually according to its tolerance. The final L-dopa dose is variable among patients, ranging from 0.8 mg/k/d to 30 mg/k/d (32; 29; 34; 04; 10; 26; 18).

Monoamine oxidase inhibitors. In patients with poor response and tolerance to L-dopa, treatment with selegiline, a selective monoamine oxidase B inhibitor, provides benefit and may allow further increases, even doubling of the L-dopa dose (06; 12; 34; 04; 10; 18). It has been postulated that the early introduction of selegiline in poor L-dopa-responder patients improves the overall treatment outcome (34). However, despite some favorable reports, selegiline has been ineffective in other patients (05; 35).

Selegiline is usually administered once daily, with reported dose ranges from 2.5 to 15 mg daily or 0.1 to 0.4 mg/k/d. Dose-dependent side effects reported in tyrosine hydroxylase deficient patients include hyperkinesia, rigidity, and sleep disorder (04). Additional side effects include nausea, dizziness, dry mouth, confusion, and orthostatic hypotension.

Monoamine oxidase hypertensive crisis precipitated by food rich in tyramine do not occur with selegiline doses below 10 mg/d. Because patients with tyrosine hydroxylase deficiency rarely take more than 10 mg/d, they do not need to be on a tyramine-restricted diet; it can be given safely in combination with L-dopa (26).

Management of L-dopa induced dyskinesias. Poor tolerance to L-dopa manifesting in the form of L-dopa-induced dyskinesias is a common feature of defects of dopamine synthesis; such movements may be intolerable and preclude treatment. Dyskinesias can also be induced by other dopaminergic agents (15).

In tyrosine hydroxylase-deficient patients, L-dopa-induced dyskinesias are of variable intensity and appear early in the course of treatment regardless of the age at which treatment was initiated. They have been characterized as chorea of the face, limbs, and trunk of variable intensity, and more rarely by prominent ballism. They are precipitated by increases in the dose of L-dopa and also by febrile illnesses and stress. Occasionally, they can be intolerable, especially in those cases presenting in the form of ballism (26).

L-dopa-induced dyskinesias in tyrosine hydroxylase-deficient patients are initially managed by slowing down the escalation of L-dopa dose either by decreasing the L-dopa to the previously tolerated dose or by postponing further increases of L-dopa until dyskinesias decrease or recede. When these measures are insufficient, amantadine may be added (26).

Amantadine is used in patients with Parkinson disease suffering from motor fluctuations and dyskinesias. Its mechanism of action is not completely clear. Side effects include nausea, vomiting, and livedo reticularis. Amantadine at 4 to 6 mg/k/d has been tried in 2 tyrosine hydroxylase-deficient patients with L-dopa-induced dyskinesias that were severe enough to prevent escalation of their L-dopa therapy. Patients showed a favorable response with no adverse effects, and the dose of L-dopa could then be further increased (26).

Symptomatic treatment. Treatment with anticholinergics and benzodiazepines has been used in some patients with tyrosine hydroxylase deficiency for the symptomatic management of dystonia and oculogyric crises. However, the response to these drugs is often disappointing (12; Zafiriou et al 2009; 04; 28).

In addition to pharmacological therapy, patients are placed on a rehabilitation program including physical, occupational, and speech therapy.

Management of autonomic dysfunction has not been necessary in these patients because initiation of L-dopa treatment, even at very small doses, usually corrects sympathetic dysfunction (26).

Other therapeutic strategies. Bilateral subthalamic nucleus deep brain stimulation was performed in a 6-year-old child with tyrosine hydroxylase deficiency exhibiting prominent dystonia and infantile parkinsonism that was medically intractable. After surgery, his condition improved significantly and his L-dopa treatment could be reduced (29). Although it is too soon to know, deep-brain stimulation may be an option for tyrosine hydroxylase-deficient patients with minimal or no response to dopaminergic treatment or with intolerable L-dopa-induced dyskinesias.

References

01: Bijarnia-Mahay S, Jain V, Thony B. Tyrosine hydroxylase deficiency—clinical insights and a novel deletion in TH gene in an Indian patient. JIMD Rep 2020;53(1):12-5. PMID 32395404
02: Cassani E, Barichella M, Ferri V, et al. Protein-redistribution diet in a case of tyrosine hydroxylase enzyme deficiency. Mov Disord 2017;32(5):794-5. PMID 28370247
03: Castaigne P, Rondot P, Ribadeau-Dumas JL, Said G. Progressive extra-pyramidal disorder in 2 young brothers: remarkable eff ects of treatment with L-dopa. Rev Neurol 1971;124:162-6. PMID 5564861
04: Chi CS, Lee HF, Tsai CR. Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatr Neurol 2012;46(2):77-82. PMID 22264700
05: de Lonlay P, Nassogne MC, van Gennip AH, et al. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. J Inherit Metab Dis 2000; 23:819-25. PMID 11196107
06: Dionisi-Vici C, Hoffmann GF, Leuzzi V, et al. Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr 2000;136:560-2. PMID 10753262
07: Fossbakk A, Kleppe R, Knappskog PM, Martinez A, Haavik J. Functional studies of tyrosine hydroxylase missense variants reveal distinct patterns of molecular defects in Dopa-responsive dystonia. Hum Mutat 2014;35(7):880-90. PMID 24753243
08: Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001;56(2):260-3. PMID 11160968
09: Furukawa Y, Kish SJ, Fahn S. Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol 2004;55(1):147-8. PMID 14705130
10: Giovanniello T, Claps D, Carducci C, et al. A new tyrosine hydroxylase genotype associated with early-onset severe encephalopathy. J Child Neurol 2012;27(4):523-5. PMID 21940685
11: Goswami JN, Sankhyan N, Singhi PD. An Indian family with tyrosine hydroxylase deficiency. Indian Pediatr 2017;54(6):499-501. PMID 28667724
12: Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003;54(suppl 6):S56-65. PMID 12891655
13: Katus LE, Frucht SJ. An unusual presentation of tyrosine hydroxylase deficiency. J Clin Mov Disord 2017;4:18. PMID 29225908
14: Korner G, Noain D, Ying M, et al. Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency. Brain 2015;138(10):2948-63.** PMID 26276013
15: Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011;10(8):721-33. PMID 21777827
16: Kuseyri Hubschmann O, Horvath G, Cortès-Saladelafont E, et al. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nat Commun 2021a;12(1):5529. PMID 34545092
17: Kuseyri Hubschmann O, Mohr A, Friedman J, et al. Brain MR patterns in inherited disorders of monoamine neurotransmitters: An analysis of 70 patients. J Inherit Metab Dis 2021b;44(4):1070-82. PMID 33443316
18: Leuzzi V, Mastrangelo M, Giannini MT, Carbonetti R, Hoffmann GF. Neuromotor and cognitive outcomes of early treatment in tyrosine hydroxylase deficiency type B. Neurology 2017;88(5):501-2. PMID 28039315
19: Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. New evidence for neurotransmitter influences on brain development. Trends Neurosci 1997;20(6):269-74. PMID 9185309
20: Li XY, Yang YM, Li LB, et al. Identification of TH Variants in Chinese dopa-responsive dystonia patients and long-term outcomes. Front Neurol 2021;12:644910. PMID 34054692
21: Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5(7):1023-8. PMID 8817341
22: Moller LB, Romstad A, Paulsen M, et al. Pre- and postnatal diagnosis of tyrosine hydroxylase deficiency. Prenat Diagn 2005;25(8):671-5. PMID 16049992
23: Ormazabal A, Serrano M, Garcia-Cazorla A, et al. Deletion in the tyrosine hydroxylase gene in a patient with a mild phenotype. Mov Disord 2011;26(8):1558-60. PMID 21465550
24: Pons R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit Metab Dis 2009;32(3):321-32. PMID 19107571
25: Pons R, Serrano M, Ormazabal A, et al. Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. Mov Disord 2010;25(8):1086-90. PMID 20198643
26: Pons R, Syrengelas D, Youroukos S, Orfanou I, Dinopoulos A, Cormand B, et al. Levodopa-Induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013;28(8):1058-63. PMID 23389938
27: Schiller A, Wevers RA, Steenbergen GC, Blau N, Jung HH. Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 2004;63(8):1524-6. PMID 15505183
28: Stamelou M, Mencacci NE, Cordivari C, et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 2012;79(5):435-41. PMID 22815559
29: Tormenti MJ, Tomycz ND, Coffman KA, Kondziolka D, Crammond DJ, Tyler-Kabara EC. Bilateral subthalamic nucleus deep brain stimulation for dopa-responsive dystonia in a 6-year-old child. EC. J Neurosurg Pediatr 2011;7(6):650-3. PMID 21631204
30: Tristán-Noguero A, Díez H, Jou C, et al. Study of a fetal brain affected by a severe form of tyrosine hydroxylase deficiency, a rare cause of early parkinsonism. Metab Brain Dis 2016;31(3):705-9.** PMID 26686676
31: van den Heuvel LP, Luiten B, Smeitink JA, et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population. Hum Genet 1998;102(6):644-6. PMID 9703425
32: Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010;133(pt 6):1810-22. PMID 20430833
33: Yeung WL, Lam CW, Hui J, Tong SF, Wu SP. Galactorrhea-a strong clinical clue towards the diagnosis of neurotransmitter disease. Brain Dev 2006;28(6):389-91. PMID 16376043
34: Yeung WL, Wong VC, Chan KY, et al. Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol 2011;26(2):179-87. PMID 20823027
35: Zafeiriou DI, Willemsen MA, Verbeek MM, Vargiami E, Ververi A, Wevers R. Tyrosine hydroxylase deficiency with severe clinical course. Mol Genet Metab 2009;97:18-20. PMID 19282209

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Roser Pons MD

Dr. Pons of the University of Athens in Greece has no relevant financial relationships to disclose.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Patient Profile

Age range of presentation: 0 month to 12 years
Sex preponderance: male=female
Heredity: autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Other specified disorders of metabolism: 277.8
ICD-10: Metabolic disorders: E70-E90
OMIM: Tyrosine hydroxylase; TH: *191290

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Tyrosine hydroxylase deficiency

Differential Diagnosis

Disorders of monoamine neurotransmitter synthesis
Early infantile epileptic encephalopathy
Cerebral palsy
Neuromuscular disorders
Congenital myasthenia
- Metabolic disorders

Tyrosine hydroxylase deficiency

Tyrosine hydroxylase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Pregnancy

Dietary management

Media

References

Contributors

Author

Editor

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

Tyrosine hydroxylase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Pregnancy

Dietary management

Media

References

Contributors

Author

Editor

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

This is an article preview.
Start a Free Account
to access the full version.